• SENSEX
    NIFTY 50
Business

Launch of Trastuzumab in US market offers a sizeable opportunity for Biocon & Mylan, says Kiran Mazumdar Shaw

Updated : December 03, 2019 09:59 AM IST

We do have a growing portfolio of biosimilar antibodies for cancer, said Kiran Mazumdar Shaw, CMD, Biocon.
At the moment very much on track to achieve sales target of $ 1 billion for biosimilars  by FY22, said Kiran Mazumdar Shaw.

You May Also Like

Live TV
Advertisement